Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash

MPM BioImpact fully liquidated its MoonLake Immunotherapeutics position in Q3, selling 313,571 shares for an estimated $14.8 million and eliminating a stake that had been 2.6% of the fund's AUM. MoonLake (NASDAQ:MLTX) trades at $13.80 with a market cap of ~$977.7M and TTM net loss of $210.5M; the stock has plunged (≈74% Y/Y and nearly 90% in one day after mixed Phase 3 results), faces a class-action suit, and yet reported $380.5M cash with runway into H2 2027 and a Dec. 15 FDA meeting on its sonelokimab program.

Analysis

Market structure: MPM’s $14.8m full exit (≈1.5% of MLTX market cap) amplifies forced-sell narrative for small-cap clinical biotechs and temporarily increases free float and effective supply for MLTX, pressuring price discovery. Winners are large, established immunology names and liquid biotech ETFs (XBI, IBB) that will likely attract risk-off flows; losers are thinly traded clinical-stage names (MLTX, MBX, CRNX) where single-news events create 50–90% intraday moves.

Risk assessment: Tail risks include adverse FDA feedback at the Dec 15 meeting or a negative class-action outcome that could wipe out cash runway (MLTX reports cash to H2 2027) — both could drive near-term downside >50%. Timeline: immediate (days) — elevated IV and liquidity stress; short-term (weeks) — FDA/legal catalysts; long-term (quarters) — binary restructure/partnering outcomes determining 2–5x upside or permanent impairment. Hidden deps: trial endpoint nuances, CRO data integrity, and partner willingness to pay for later-stage trials.

Trade implications: Direct plays: small, asymmetric option exposure to MLTX around Dec 15 (limited-premium long call or call spread) and protective put spreads on XBI to hedge sector spillovers. Pair trade: go long CGEM (3% portfolio) vs short XBI (3%) to capture relative safety/managerial conviction. Rotate: trim small-cap clinical exposure to ≤5% and redeploy into large-cap healthcare/medtech (+5%) to lower gamma risk.

Contrarian angles: Consensus prices in regulatory failure but underweights the company’s cash runway and the high binary upside if FDA signals an acceptable evidence path — comparable small-biotech rebounds have been 2–6x post-clarity. The exit may be liquidity-driven, creating mispricing: if MLTX < $15 and implied vol >80%, limited-premium long options offer asymmetric payoff; conversely, persistent litigation or negative FDA language would justify a fast re-rate to zero for holders.

Key Decisions for Investors

• Establish a speculative 0.5–1.0% portfolio long in MLTX via a limited-premium option structure: buy Jan 2026 call spread (buy $15 / sell $30) sized so max premium = 0.5% portfolio; initiate 10–14 days before the Dec 15 FDA meeting and exit within 3 trading days after unless guidance changes.
• Initiate a relative-value pair: go long CGEM (ticker CGEM) for 3% of portfolio while shorting XBI (or equivalent small-cap biotech ETF) for 3% to capture defensive rotation away from binary clinical risk; rebalance after 90 days or after MLTX FDA clarity.
• Reduce aggregate small-cap clinical-stage biotech exposure (MLTX, MBX, CRNX and peers) to ≤5% of portfolio within 2 weeks; redeploy the freed 3–7% into large-cap healthcare/medtech names or ETFs (e.g., XLV, IHI) to lower idiosyncratic gamma risk.
• Buy protective put spreads on a 2–3% notional of biotech exposure (e.g., XBI) with 3–6 month expiries to cap sector downside through the Dec 15 catalyst window; use 25–30% stop-loss on option premiums and reassess post-FDA comments.